research Editorial Comment
More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
Search
for
Sort by
Research
120-150 / 1000+ results
research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
research CLINICAL OBSERVATION: HYPONATREMIA ASSOCIATED WITH DIURETIC USE AND URINARY RETENTION IN AN OLDER MAN
Older adults using diuretics should manage water intake carefully to avoid low sodium levels.
research Combination of finasteride and tamsulosine in the treatment of male lower urinary tract symptoms: What patients are thinking about?
Patients follow treatment well, but many change medicines; good information helps compliance.
research MP-09.08
The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
research Ejaculatory dysfunction in the treatment of lower urinary tract symptoms
Treatments for urinary symptoms often cause ejaculatory problems.
research Current treatment of BPH
TURP is the best treatment for BPH, but some patients prefer medications like alpha-blockers and finasteride.
research Targeting a fibrotic bottleneck may provide an opening in the treatment of LUTS
New treatments targeting fibrosis could improve urinary symptoms in BPH.
research 332 Recognizing and Treating Undiagnosed Erectile Dysfunction (ED) in Patients Presenting With Lower Urinary Tract Symptoms (LUTS)
Many patients with lower urinary tract symptoms also have undiagnosed erectile dysfunction, which improves with treatment.
research Finasteride plus doxazosin combination tops in BPH
research Epidemiology and treatment modalities for the management of benign prostatic hyperplasia
More men are getting benign prostatic hyperplasia, and there are many treatments, from medication to surgery, with new methods being developed.
research Editorial Comment
Self-management can help improve symptoms of benign prostatic hyperplasia.
research Дослідження ПРОСПЕКТ IV (ПРОСтамол: ПЕрспективи Комбінованої Терапії) у хворих на доброякісну гіперплазію передміхурової залози
"Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
research Cystitis Due to Cytoxan: Case Report
A woman developed severe bladder inflammation after cancer treatment with Cytoxan.
research 559 Visualization of sweat suppression following botulinum toxin A by soluble microneedle arrays
Microneedle arrays deliver botulinum toxin effectively for sweat suppression, similar to injections.
research Review: Adding α1-blockers to 5α-reductase inhibitors improves lower urinary tract symptoms in men
Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
research The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial
Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
research BPH: epidemiology and comorbidities.
BPH is common in older men and often occurs with other age-related health issues.
research Postoperative Urinary Retention is an Independent Predictor of Short-Term and Long-Term Future Bladder Outlet Procedure in Men
Older men with postoperative urinary retention are more likely to need future bladder procedures.
research Dutasteride for the treatment of benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
research Micturitional disturbance in a patient with adrenomyeloneuropathy (AMN)
Adrenomyeloneuropathy (AMN) can cause bladder problems due to nerve damage.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research AB40. Sexual side effects of medical treatment of BPH
BPH treatments can cause sexual side effects affecting quality of life.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial
Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
research Molecular docking simulation studies on potent butyrylcholinesterase inhibitors obtained from microbial transformation of dihydrotestosterone
Metabolite 7 is a strong inhibitor for Alzheimer's disease management.
research Editorial Comments
research The effect of the combined drug Yuperio with bisoprolol on the dynamics of the heart with dilation of the left chambers, the development of which is due to non-compactness of the myocardium of the left ventricle
Yuperio combined with bisoprolol improves heart function in patients with dilated cardiomyopathy.
research Risks and side effects in the medical management of benign prostatic hyperplasia
Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.
research Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
Dutasteride is more effective than finasteride in reducing urinary retention and surgery risks in people aged 65 and older.